Roots Analysis has announced the addition of “Non-Viral Transfection Reagents and Systems Market, 2nd Edition, 2023-2035” report to its list of offerings.
The study presents an in-depth analysis, across different geographies, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
- An executive summary of the insights captured during our research. It offers a high-level view on the current state of non-viral transfection reagents and systems market and its likely evolution in the mid-long term.
- A general overview of non-viral transfection reagents and systems, highlighting details on transfection methods and its applications, such as advanced therapy medicinal product development, gene silencing, bioproduction of therapeutic protein and stem cell engineering. It also provides information on the different methods of transfection and various other methods.
- A detailed assessment of the overall market landscape of the companies developing non-viral transfection reagents, based on several relevant parameters.
- A detailed assessment of the overall market landscape of the companies developing electroporation-based non-viral transfection systems. The relevant parameters used for the assessment include, compatible cell type and several others.
- A detailed assessment of the overall market landscape of the companies developing other non-viral transfection systems. The relevant parameters used for the assessment include, compatible cell type, and type of molecule delivered. It also features information on the other non-viral transfection systems suppliers based on various parameters.
- An in-depth company competitiveness analysis of non-viral transfection reagents and system suppliers based in North America, Europe and Asia-Pacific. The analysis compares various suppliers based on supplier strength and several other parameters.
- A detailed technology competitiveness analysis of electroporation transfection systems and other non-viral transfection systems, taking into consideration the supplier strength and product portfolio strength in terms of several parameters.
- Tabulated profiles of key players engaged in the development of non-viral transfection reagents and systems (shortlisted based on the type of carrier used, compatible cell type and several other parameters). Each profile includes a brief overview of the company, financial information (if available), recent developments and an informed future outlook.
- An in-depth analysis of over 80 cell (including TCR and CAR-T cell) and gene therapy developers that are likely to partner with non-viral transfection reagent and system suppliers, based on several relevant parameters.
- A review of the various non-viral focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring various insightful representations, based on various factors.
- An in-depth analysis of close to 870 patents that have been filed / granted related to non-viral transfection systems, since 2019, highlighting key trends associated with these patents, across type of patent, publication year, application year, geography, type of applicant and various other factors. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
- A detailed analysis of more than 450 peer-reviewed, scientific articles focused on non-viral transfection reagents and systems that have been published since 2015, based on year of publication, type of publication and various other parameters.
- An insightful framework to understand the pricing strategy of the non-viral transfection reagents offered by a company, along with its competitive position in the market.
The future opportunity within the non-viral transfection reagents and systems market has been analyzed across the following segments:
- Non-Viral Based Transfection Methods
- Chemical-based Methods
- Physical-based Methods
- Other Methods
- End-Users
- Academic And Research Institutions
- Stem Pharmaceutical Companies
- Other End-Users
- Area Of Application
- Clinical Applications
- Research Applications
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Key Companies covered in the report
- BEX
- Bio-Rad Laboratories
- BTX
- Celsion Corporation
- Genprex
- Inovio Pharmaceuticals
- MaxCyte
- MilliporeSigma
- NepaGene
- OZ Biosciences
- Thermo Fisher Scientific
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/non-viral-transfection/307.html
Learn from experts: do you know about these emerging industry trends?
Investment Opportunities in Women’s Digital Health
Genotoxicity Testing: Unlocking the Future Safety Assessment Opportunities
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
